On Sunday, October 6, CHMEDITECH participated in AMAC Asia 2024 held at the Kowloon Shangri-La in Hong Kong.

AMAC is an abbreviation for "Asia Medical Aesthetic Congress", and it is a place to introduce the latest trends in aesthetic knowledge and share the successful experiences and protocols of global leaders in the field of aesthetic surgery. AMAC of this year was meaningful as it was the first offline event held after the COVID-19 pandemic, and the participants were comprised of 90% local Hong Kong doctors and 10% agency representatives.

At 10:30 AM, in the Fanling Room, there was a lecture(Exosomes: Revive NX - Development and Application of Probiotic-Derived Extracellular Vesicles) on the CELLTERMI REVIVE NX product by Eun-gyung Cho, Managing Director of CHAMEDITECH H&B science center.

In addition, Director Sang-yub Kim of JF Clinic in Seoul demonstrated REVIVE NX in combination with the CUREJET product handled by WINGPROFIT, a local CHAMEDITECH distributor of Hong Kong.

CHAMEDITECH official said, "It was a meaningful time to check the trends in the Asian cosmetic surgery market through successful cases of cosmetic procedures and management, and to widely promote CELLTERMI REVIVE NX and CHAMEDITECH Exosomes".

REVIVE NX, which was promoted at AMAC Asia 2024, is a premium topical skin booster product from CHAMEDITECH's cosmetics brand CELLTERMI. It contains CHA-Nidogen-1, which is derived from nidogen, one of the four major proteins of the skin basement membrane, and exosomes derived from lactobacillus paracasei, and is currently being sold as a skin booster for export.